References

Atherosclerotic cardiovascular disease risk assessment: an American Society for Preventive Cardiology clinical practice statement

10.1016/j.ajpc.2022.100335 · 2022 · External reference

Association of interleukin-6 and interleukin-18 with cardiovascular disease in older adults: atherosclerosis risk in communities study

10.1093/eurjpc/zwad197 · 2023 · External reference

Mechanisms of plaque formation and rupture

10.1161/circresaha.114.302721 · 2014 · External reference

Comparative analysis of atherosclerotic cardiovascular disease burden between ages 20–54 and over 55 years: insights from the Global Burden of Disease Study 2019

10.1186/s12916-024-03527-4 · 2024 · External reference

Inflammatory and metabolic markers mediate the association of hepatic steatosis and fibrosis with 10-year ASCVD risk

10.1080/07853890.2025.2486594 · 2025 · External reference

Early-onset atherosclerotic cardiovascular disease

10.1093/eurjpc/zwae240 · 2025 · External reference

2021 ESC guidelines on cardiovascular disease prevention in clinical practice: developed by the Task Force for Cardiovascular Disease Prevention in Clinical Practice with representatives of the European Society of Cardiology and 12 medical societies with the special contribution of the European Association of Preventive Cardiology (EAPC)

10.1093/eurheartj/ehab484 · 2021 · External reference

2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines

10.1016/j.jacc.2019.03.010 · 2019 · External reference

2024 ESC guidelines for the management of chronic coronary syndromes: developed by the Task Force for the Management of Chronic Coronary Syndromes of the European Society of Cardiology (ESC) endorsed by the European Association for Cardio-Thoracic Surgery (EACTS)

10.1093/eurheartj/ehae177 · 2024 · External reference

Pleiotropic effects of statins

10.1146/annurev.pharmtox.45.120403.095748 · 2005 · External reference

Pleiotropic effects of statins

10.4103/2230-8210.163106 · 2015 · External reference

The effect of different statin-based lipid-lowering strategies on C-reactive protein levels in patients with stable coronary artery disease

10.1002/clc.24301 · 2024 · External reference

Effect of statin use on inflammation and immune activation biomarkers in HIV-infected persons on effective antiretroviral therapy

10.1089/aid.2020.0127 · 2020 · External reference

Statins and nitric oxide reduce C-reactive protein production while inflammatory conditions persist

10.1016/j.molimm.2005.06.045 · 2006 · External reference

Inflammation during percutaneous coronary intervention—prognostic value, mechanisms and therapeutic targets

10.3390/cells10061391 · External reference

Dissecting the IL-6 pathway in cardiometabolic disease: a Mendelian randomization study on both IL6 and IL6r

10.1111/bcp.15191 · 2022 · External reference

Inflammation and cardiovascular disease: from mechanisms to therapeutics

10.1016/j.ajpc.2020.100130 · 2020 · External reference

Integrating the interleukins in the biomarker panel for the diagnosis and prognosis of patients with acute coronary syndromes: unraveling a multifaceted conundrum

10.3390/diagnostics15101211 · 2025 · External reference

Targeting IL-6 trans-signalling: past, present and future prospects

10.1038/s41577-023-00856-y · 2023 · External reference

IL-6 promotes cell adhesion in human endothelial cells via microRNA-126–3p suppression

10.1016/j.yexcr.2020.112094 · 2020 · External reference

Classical IL-6 signaling: a promising therapeutic target for pulmonary arterial hypertension

10.1172/jci120415 · 2018 · External reference

Interleukin-6: designing specific therapeutics for a complex cytokine

10.1038/nrd.2018.45 · 2018 · External reference

Role of interleukin-6 in vascular health and disease

10.3389/fmolb.2021.641734 · 2021 · External reference

Interleukin-6 signalling, lipoprotein (a) lowering and cardiovascular disease: a Mendelian randomisation study (Abstr)

10.1093/eurheartj/ehae666.2869 · 2024 · External reference

Proteogenomic data integration reveals Cxcl10 as a potentially downstream causal mediator for IL-6 signaling on atherosclerosis

10.1161/circulationaha.123.064974 · 2024 · External reference

Mir-223 exerts translational control of proatherogenic genes in macrophages

10.1161/circresaha.121.319120 · 2022 · External reference

Mettl14 mediates the inflammatory response of macrophages in atherosclerosis through the Nf-Κb/IL-6 signaling pathway

10.1007/s00018-022-04331-0 · 2022 · External reference

Role of Adar2-mediated innate immune responses in vascular inflammation and atherosclerosis

10.1093/cvr/cvae088.169 · 2024 · External reference

Direct IL-6 inhibition prevents arterial thrombosis by reducing collagen-mediated platelets activation (Abstr)

2024 · External reference

Dnmt3a modifies the anti-inflammatory effect of the IL-6 classical pathway in macrophages to change the atherosclerosis burden (Abstr)

2024 · External reference

Mendelian randomization studies in atherosclerotic cardiovascular diseases

10.12997/jla.2024.13.3.280 · 2024 · External reference

Patterns of inflammatory activation in cardiovascular disease: insights from the randomized colchicine PCI trial (Abstr)

10.1161/circ.148.suppl_1.16734 · 2023 · External reference

Associations of rheumatoid factor, rheumatoid arthritis, and interleukin-6 inhibitor with the prognosis of ischemic stroke: a prospective multicenter cohort study and Mendelian randomization analysis

10.1007/s12975-023-01161-5 · 2024 · External reference

Interleukin-6 and cardiovascular events in healthy adults

10.1016/j.jacadv.2024.101063 · 2024 · External reference

Interleukin-6 plasma levels are elevated in patients with acute myocardial infarction and predict death or recurrent infarction within 1 year—a case-control study (Abstr)

10.1093/eurheartj/ehad655.1383 · 2023 · External reference

Cardiovascular calcifications are correlated with inflammation in hemodialysis patients

10.3390/medicina59101801 · 2023 · External reference

Relationship between serum interleukin-6 levels and severity of STEMI undergoing percutaneous xoronary intervention (Abstr)

2024 · External reference

The prognostic value of serum interleukin-6 concentrations for 9 cardiovascular and mortality outcomes: the Cross Cohort Collaboration (CCC)

10.1016/j.jacc.2026.04.015 · 2026 · External reference

Discovery of four plasmatic biomarkers potentially predicting cardiovascular outcome in peripheral artery disease

10.1038/s41598-022-23260-3 · 2022 · External reference

Coronary atherosclerosis, cardiac troponin, and interleukin-6 in patients with chest pain

10.1016/j.jcmg.2022.03.016 · 2022 · External reference

The IL-6 Rs1800795 and Rs1800796 polymorphisms are associated with coronary artery disease risk

10.1111/jcmm.15246 · 2020 · External reference

Inflammatory biomarkers interleukin-6 and C-reactive protein and outcomes in stable coronary heart disease: experiences from the stability (stabilization of atherosclerotic plaque by initiation of darapladib therapy) trial

10.1161/jaha.116.005077 · 2017 · External reference

Cardiovascular risk factors: the effects of ageing and smoking on the immune system, an observational clinical study

10.3389/fimmu.2022.968815 · 2022 · External reference

Genetic and environmental determinants of population variation in interleukin-6, its soluble receptor and C-reactive protein: insights from identical and fraternal twins

10.1016/j.bbi.2015.05.010 · 2015 · External reference

Effect of a nut-enriched low-calorie diet on body weight and selected markers of inflammation in overweight and obese stable coronary artery disease patients: a randomized controlled study

10.1038/s41430-020-00819-9 · 2021 · External reference

The interleukin-6 gene promoter polymorphism -174 and atherosclerotic events in overweight transplanted patients

10.1155/2011/803429 · 2011 · External reference

Efficacy of intermittent fasting in the management of chronic plaque psoriasis: a phase IIb clinical trial

10.4103/idoj.idoj_635_24 · 2025 · External reference

Can intervals enhance the inflammatory response and enjoyment in upper-body exercise?

10.1007/s00421-017-3602-4 · 2017 · External reference

Exercise training reduces circulating cytokines in male patients with coronary artery disease and type 2 diabetes: a pilot study

10.14814/phy2.15634 · 2023 · External reference

Comparison of interleukin-6 and high-sensitivity C-reactive protein for cardiovascular risk assessment: findings from the mesa study

10.1016/j.atherosclerosis.2024.117461 · 2024 · External reference

Awareness and perceptions of cardiologists towards systemic inflammation in atherosclerotic cardiovascular disease: a multi-national survey across 5 geographical regional sub-groups (Abstr)

10.1093/eurheartj/ehae666.1315 · 2024 · External reference

Population differences in proinflammatory biology: Japanese have healthier profiles than Americans

10.1016/j.bbi.2010.11.013 · 2011 · External reference

Effect of a single dose of the interleukin-6 receptor antagonist tocilizumab on inflammation and troponin T release in patients with non-ST-elevation myocardial infarction: a double-blind, randomized, placebo-controlled phase 2 trial

10.1093/eurheartj/ehw171 · 2016 · External reference

Cardiovascular safety of tocilizumab versus etanercept in rheumatoid arthritis: a randomized controlled trial

10.1002/art.41095 · 2020 · External reference

Short-term application of tocilizumab during myocardial infarction (STAT-MI)

10.1007/s00296-017-3842-y · 2018 · External reference

Interleukin-6 inhibition in ST-elevation myocardial infarction: immune cell profile in the randomised ASSAIL-MI trial

10.1016/j.ebiom.2022.104013 · 2022 · External reference

The effects of interleukin-6-receptor inhibition on monocytes in STEMI: a substudy of the ASSAIL-MI trial

10.1016/j.ebiom.2025.105960 · 2025 · External reference

Randomized trial of interleukin-6 receptor inhibition in patients with acute ST-segment elevation myocardial infarction

10.1016/j.jacc.2021.02.049 · 2021 · External reference

Neutrophil extracellular traps in ST-segment elevation myocardial infarction: reduced by tocilizumab and associated with infarct size

10.1016/j.jacadv.2024.101193 · 2024 · External reference

Long-term safety and efficacy of sarilumab with or without background csDMARDs in rheumatoid arthritis

10.1093/rheumatology/kead062 · 2023 · External reference

Long-term safety and efficacy of sirukumab for patients with rheumatoid arthritis who previously received sirukumab in randomised controlled trials (SIRROUND-LTE)

10.1136/rmdopen-2020-001465 · 2021 · External reference

Olokizumab plus methotrexate: safety and efficacy over 106 weeks of treatment

10.1136/ard-2023-225473 · 2024 · External reference

IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial

10.1016/s0140-6736(21)00520-1 · 2021 · External reference

Efficacy and safety of interleukin-6 inhibition with ziltivekimab in patients at high risk of atherosclerotic events in Japan (RESCUE-2): a randomized, double-blind, placebo-controlled, phase 2 trial

10.1016/j.jjcc.2023.05.006 · 2023 · External reference

Wcn25-888 design of the ZEUS trial: interleukin 6 inhibition with ziltivekimab for cardiovascular protection in chronic kidney disease

10.1016/j.ekir.2024.11.1354 · 2025 · External reference

IL-6 inhibition with clazakizumab in patients receiving maintenance dialysis: a randomized phase 2b trial

10.1038/s41591-024-03043-1 · 2024 · External reference

Inflammatory biomarkers and long-term outcome in young stable patients 3 months after a first myocardial infarction (Abstr)

2023 · External reference

Development and validation of the American Heart Association's prevent equations

10.1161/circulationaha.123.067626 · 2024 · External reference

Development and validation of Qrisk3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study

10.1136/bmj.j2099 · 2017 · External reference

The effects of statins on cardiovascular and inflammatory biomarkers in primary prevention: a systematic review and meta-analysis

10.1016/j.hlc.2023.04.300 · 2023 · External reference

2025 focused update of the 2019 ESC/EAS guidelines for the management of dyslipidaemias

10.1016/j.atherosclerosis.2025.120479 · 2025 · External reference

Interleukin-6 level is a powerful predictor of long-term cardiovascular mortality in patients with acute coronary syndrome

10.1016/j.vph.2020.106806 · 2020 · External reference

Interleukin-6 as an independent predictor of future cardiovascular events in high-risk Japanese patients: comparison with C-reactive protein

10.1016/j.cyto.2010.12.005 · 2011 · External reference

Serum midkine level and its association with subclinical coronary artery calcification and carotid atherosclerosis in chronic kidney disease

10.1186/s12882-025-04066-7 · 2025 · External reference

Association between IL-6 and the extent of coronary atherosclerosis in the veterans affairs diabetes trial (VADT)

10.1016/j.atherosclerosis.2008.07.031 · 2009 · External reference

Multi-modality biomarkers in the early prediction of ischaemic heart disease in middle-aged men during a 21-year follow-up

10.1186/s12872-021-01886-x · 2021 · External reference

Inflammatory markers as independent predictors for stroke outcomes

10.1002/brb3.1922 · 2021 · External reference

Frontiers and hotspot evolution of Nlrp3 inflammasome in myocardial infarction research: a bibliometric analysis from 2013 to 2024

10.1155/cdr/5178894 · 2025 · External reference

Inflammatory cytokines and ischemic stroke risk

10.1212/wnl.0000000000007416 · 2019 · External reference

Intensive lowering of LDL cholesterol levels with evolocumab in autoimmune or inflammatory diseases: an analysis of the Fourier trial

10.1161/circulationaha.124.072756 · 2025 · External reference

Atherosclerotic cardiovascular disease in inflammatory bowel disease: the role of chronic inflammation and platelet aggregation

10.3390/medicina59030554 · 2023 · External reference

A study of oxidative stress, inflammation, and endothelial dysfunction in diabetic and nondiabetic chronic kidney disease pre-dialysis patients

10.4103/ijn.ijn_222_22 · 2023 · External reference

Evaluation of inflammatory status in chronic kidney disease patients and a comparison between hemodialysis and peritoneal dialysis patients

10.7759/cureus.69443 · 2024 · External reference

Elevated remnant cholesterol and atherosclerotic cardiovascular disease in diabetes: a population-based prospective cohort study

10.1007/s00125-023-06016-0 · 2023 · External reference

Common and novel markers for measuring inflammation and oxidative stress ex vivo in research and clinical practice-which to use regarding disease outcomes?

10.3390/antiox10030414 · 2021 · External reference

Analytical evaluation of the automated interleukin-6 assay on the Roche cobas E602 analyzer

10.1093/labmed/lmae064 · 2025 · External reference

Inflammatory state does not affect the antiplatelet efficacy of potent P2y12 inhibitors in ACS

10.1080/09537104.2020.1766670 · 2021 · External reference

Statins: mechanism of action and effects

10.1111/j.1582-4934.2001.tb00172.x · 2001 · External reference

Dual pathway inhibition with rivaroxaban and aspirin reduces inflammatory biomarkers in atherosclerosis

10.1097/fjc.0000000000001382 · 2023 · External reference

2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force for Diabetes, Pre-diabetes, and Cardiovascular Diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD)

10.1093/eurheartj/ehz486 · 2020 · External reference

Effects of GLP-1 receptor agonists on mitochondrial function, inflammatory markers and leukocyte-endothelium interactions in type 2 diabetes

10.1016/j.redox.2023.102849 · 2023 · External reference

Combining glucagon-like peptide-1 receptor agonists (GLP-1RAS) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) in patients with type 2 diabetes Mellitus (T2DM)

10.1186/s12933-023-01798-4 · 2023 · External reference

Inflammation and cholesterol as predictors of cardiovascular events among 13970 contemporary high-risk patients with statin intolerance

10.1161/circulationaha.123.066213 · 2024 · External reference